Bertil Damato will oversee the provision of clinical care to patients with an ocular tumour and develop a research group to focus on ocular melanoma and other eye tumours.
The positive results of the world\u2019s first gene therapy trial for a genetic cause of blindness known as choroideremia have been reported in this week\u2019s edition of Nature Medicine.
Millions of people are to be given access to digital treatment for insomnia as an alternative to sleeping pills. Study by Colin Espie et al shows that Sleepio improves wellbeing in nearly three quarters of participants.
Researchers at the Sleep and Circadian Neuroscience Institute (SCNi) have been working with visual artist Martin Kohout to reveal the stories of the night-shift workers who keep London running.
In a laboratory study in Oxford, researchers have shown how it might be possible to reverse blindness using gene therapy to reprogram cells at the back of the eye to become light sensitive.
Researchers have started a new gene therapy clinical trial to treat X-linked retinitis pigmentosa (XLRP), the most common cause of blindness in young people.
Circadian Therapeutics has been established to identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.
A spinout company from our Department, OxSight, has reported that in a recent UK-wide trial its smart glasses helped sight impaired and blind people to navigate independently, avoid collisions and see in the dark.
Pioneering gene therapy has restored some vision to John Radcliffe Hospital patients with a rare form of genetic blindness for as long as four years, raising hopes it could be used to cure common causes of vision loss, new University of Oxford research published today shows.
A patient who is the first in the UK to receive the world\u2019s most advanced 'bionic eye' has been able to read the time for the first time in more than five years.
![\"Bertil](\"https://www.ndcn.ox.ac.uk/news/ndcn-welcomes-ocular-oncologist/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n